MedTrace Logo

A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC

NCT04102124 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-06-24

No results posted yet for this study

Summary

The aim of this trial is to evaluate SHR3680 combined with SHR3162 and SHR3680 single drug to improve Metastatic Castration Resistant Prostate Cancer Patients whether the patient's overall survival (OS) is superior to placebo.

Conditions

Interventions

DRUG

SHR3680

Tablet. Specifications of 80mg

DRUG

SHR3162

Tablet. Specifications of 10mg、40mg、50mg and 100mg

DRUG

SHR3680(Placebo)

Tablet. Specifications of 80mg

DRUG

SHR3162(Placebo)

Tablet. Specifications of 10mg、40mg、50mg and 100mg

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-08
Primary Completion
2021-08-31
Completion
2021-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04102124 on ClinicalTrials.gov